{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:29:56Z","timestamp":1777184996241,"version":"3.51.4"},"reference-count":27,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,6,19]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To characterize the demographics, disease characteristics, and treatment patterns of an inception cohort of children with juvenile psoriatic arthritis (JPsA) within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients diagnosed with JPsA within 6 months of CARRA registry enrollment were included and observed for up to 24 months. Baseline disease characteristics, treatment history, disease activity measures, and patient-reported outcomes (PROs) were captured at 6-month intervals (\u00b1 3 months) at usual care visits during the 24-month period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 306 patients were included. Patients were predominantly female (62.4%), with a median age of onset of 11.0 (IQR 6.0-14.0) years. At CARRA registry enrollment, 52.3% had polyarticular-course JPsA, median active joint count was 3.0 (IQR 1.0-6.0), 20.1% had enthesitis, 34.3% had dactylitis, 9.5% had active sacroiliitis, and 58.8% had psoriasis. Tumor necrosis factor inhibitors were used in 61.1% of patients. In total, 20.5% of patients received treatment with \u2265 2 bDMARDs or traditional synthetic DMARDs. Clinical Juvenile Arthritis Disease Activity Score in 10 joints (cJADAS-10) improved from a median of 10.0 (IQR 5.5-15.0) at baseline to 1.0 (IQR 0.0-5.0) at 24 months. Improvements were also seen in active enthesitis and active sacroiliitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this inception cohort of JPsA in the CARRA registry, half of the patients had polyarticular presentation, and the majority required advanced therapy. Regardless of the treatment used, most patients had improvements in disease activity measures and PROs, with most achieving clinically inactive disease. However, escalation of treatment was common, highlighting the unmet need for precision medicine in identifying the optimal initial drug for each individual patient.<\/jats:p>\n               <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0066","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:35:21Z","timestamp":1751358921000},"page":"1013-1020","source":"Crossref","is-referenced-by-count":1,"title":["Juvenile Psoriatic Arthritis Inception Cohort in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Characteristics and Early Disease Outcomes"],"prefix":"10.3899","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6714-4170","authenticated-orcid":false,"given":"Hemalatha","family":"Srinivasalu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Beukelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Dennos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-1936","authenticated-orcid":false,"given":"Colleen","family":"Correll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8660-0207","authenticated-orcid":false,"given":"Sarah","family":"Ringold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Stephen Balevic for the CARRA Registry Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2025100105301409000_52.10.1013.1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/anr.1780320810","article-title":"Psoriatic arthritis in children","volume":"32","author":"Southwood","year":"1989","journal-title":"Arthritis Rheum"},{"key":"2025100105301409000_52.10.1013.2","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2025100105301409000_52.10.1013.3","first-page":"1968","article-title":"Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. Pediatric rheumatology database research group","volume":"23","author":"Bowyer","year":"1996","journal-title":"J Rheumatol"},{"key":"2025100105301409000_52.10.1013.4","first-page":"1981","article-title":"The incidence of pediatric rheumatic diseases: results from the Canadian pediatric rheumatology association disease registry","volume":"23","author":"Malleson","year":"1996","journal-title":"J Rheumatol"},{"key":"2025100105301409000_52.10.1013.5","first-page":"1975","article-title":"Pediatric rheumatology in the United Kingdom: data from the British pediatric rheumatology group national diagnostic register","volume":"23","author":"Symmons","year":"1996","journal-title":"J Rheumatol"},{"key":"2025100105301409000_52.10.1013.6","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1542\/peds.90.6.950","article-title":"Epidemiology of juvenile chronic arthritis in southwestern Sweden: a 5-year prospective population study","volume":"90","author":"G\u00e4re","year":"1992","journal-title":"Pediatrics"},{"key":"2025100105301409000_52.10.1013.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(82)80747-6"},{"key":"2025100105301409000_52.10.1013.8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/BOR.0b013e328348b278","article-title":"Psoriatic juvenile idiopathic arthritis: a tale of two subgroups","volume":"23","author":"Stoll","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"2025100105301409000_52.10.1013.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160717"},{"key":"2025100105301409000_52.10.1013.10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12969-017-0160-6","article-title":"The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months","volume":"15","author":"Beukelman","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025100105301409000_52.10.1013.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202031"},{"key":"2025100105301409000_52.10.1013.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780371209"},{"key":"2025100105301409000_52.10.1013.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2010.02.005"},{"key":"2025100105301409000_52.10.1013.14","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/art.41879","article-title":"Definition and validation of the American College of Rheumatology 2021 juvenile arthritis disease activity score cutoffs for disease activity states in juvenile idiopathic arthritis","volume":"73","author":"Trincianti","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025100105301409000_52.10.1013.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.110767"},{"key":"2025100105301409000_52.10.1013.16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22411"},{"key":"2025100105301409000_52.10.1013.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2025100105301409000_52.10.1013.18","doi-asserted-by":"crossref","first-page":"SI160","DOI":"10.1093\/rheumatology\/kead496","article-title":"Do the features of juvenile psoriatic arthritis change according to age? A comprehensive evaluation of the PeRA research group registry","volume":"63","author":"Karada\u011f","year":"2024","journal-title":"Rheumatology"},{"key":"2025100105301409000_52.10.1013.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.49.9.694"},{"key":"2025100105301409000_52.10.1013.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080543"},{"key":"2025100105301409000_52.10.1013.21","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/rheumatology\/kead370","article-title":"The impact of psoriasis on wellbeing and clinical outcomes in juvenile psoriatic arthritis","volume":"63","author":"Low","year":"2024","journal-title":"Rheumatology"},{"key":"2025100105301409000_52.10.1013.22","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/acr.24537","article-title":"Juvenile spondyloarthritis in the childhood arthritis and rheumatology research alliance registry: high biologic use, low prevalence of HLA-B27, and equal sex representation in sacroiliitis","volume":"73","author":"Rumsey","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2025100105301409000_52.10.1013.23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40884","article-title":"2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025100105301409000_52.10.1013.24","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/art.41390","article-title":"New medications are needed for children with juvenile idiopathic arthritis","volume":"72","author":"Brunner","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025100105301409000_52.10.1013.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel201"},{"key":"2025100105301409000_52.10.1013.26","doi-asserted-by":"crossref","first-page":"152074","DOI":"10.1016\/j.semarthrit.2022.152074","article-title":"Physicians\u2019 vs patients\u2019 global assessments of disease activity in rheumatology and musculoskeletal trials: a meta research project with focus on reasons for discrepancies","volume":"56","author":"Lyn\u00e6s","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2025100105301409000_52.10.1013.27","first-page":"103","article-title":"Patient-physician discordance in assessment of disease activity in rheumatoid arthritis patients","volume":"46","author":"Brites","year":"2021","journal-title":"Acta Reumatol Port"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:31:10Z","timestamp":1759321870000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.3899\/jrheum.2025-0066"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0066","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}